224 related articles for article (PubMed ID: 33996267)
21. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.
Cho BC; Lee JS; Wu YL; Cicin I; Dols MC; Ahn MJ; Cuppens K; Veillon R; Nadal E; Dias JM; Martin C; Reck M; Garon EB; Felip E; Paz-Ares L; Mornex F; Vokes EE; Adjei AA; Robinson C; Sato M; Vugmeyster Y; Machl A; Audhuy F; Chaudhary S; Barlesi F
J Thorac Oncol; 2023 Dec; 18(12):1731-1742. PubMed ID: 37597750
[TBL] [Abstract][Full Text] [Related]
22. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia.
Lin CC; Doi T; Muro K; Hou MM; Esaki T; Hara H; Chung HC; Helwig C; Dussault I; Osada M; Kondo S
Target Oncol; 2021 Jul; 16(4):447-459. PubMed ID: 33840050
[TBL] [Abstract][Full Text] [Related]
23. Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer.
Rajan A; Abdul Sater H; Rahma O; Agajanian R; Lassoued W; Marté JL; Tsai YT; Donahue RN; Lamping E; Bailey S; Weisman A; Walter-Rodriguez B; Ito R; Vugmeyster Y; Sato M; Machl A; Schlom J; Gulley JL
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485188
[TBL] [Abstract][Full Text] [Related]
24. Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer.
Kang YK; Bang YJ; Kondo S; Chung HC; Muro K; Dussault I; Helwig C; Osada M; Doi T
Clin Cancer Res; 2020 Jul; 26(13):3202-3210. PubMed ID: 32299818
[TBL] [Abstract][Full Text] [Related]
25. Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.
Oaknin A; Ghamande SA; Kasamatsu Y; Gil-Martin M; Grau-Bejar JF; Garcia-Duran C; Sato M; Siddiqui A; Chaudhary SP; Vugmeyster Y; Hasegawa K
Clin Cancer Res; 2024 Mar; 30(5):975-983. PubMed ID: 38165683
[TBL] [Abstract][Full Text] [Related]
26. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.
Grenga I; Donahue RN; Gargulak ML; Lepone LM; Roselli M; Bilusic M; Schlom J
Urol Oncol; 2018 Mar; 36(3):93.e1-93.e11. PubMed ID: 29103968
[TBL] [Abstract][Full Text] [Related]
27. Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1.
Vugmeyster Y; Wilkins J; Koenig A; El Bawab S; Dussault I; Ojalvo LS; De Banerjee S; Klopp-Schulze L; Khandelwal A
Clin Pharmacol Ther; 2020 Sep; 108(3):566-574. PubMed ID: 31955412
[TBL] [Abstract][Full Text] [Related]
28. Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma.
Khasraw M; Weller M; Lorente D; Kolibaba K; Lee CK; Gedye C; I de La Fuente M; Vicente D; Reardon DA; Gan HK; Scott AM; Dussault I; Helwig C; Ojalvo LS; Gourmelon C; Groves M
Neurooncol Adv; 2021; 3(1):vdab058. PubMed ID: 34056607
[TBL] [Abstract][Full Text] [Related]
29. Risk assessment of drug-drug interaction potential for bintrafusp alfa with cytochrome P4503A4 substrates: A totality of evidence approach.
Vugmeyster Y; Locke G; Helwig C; Rolfe PA; Dong JQ; Venkatakrishnan K
Clin Transl Sci; 2022 Dec; 15(12):2838-2843. PubMed ID: 36152313
[TBL] [Abstract][Full Text] [Related]
30. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
[TBL] [Abstract][Full Text] [Related]
31. Identification of
Spira A; Awada A; Isambert N; Lorente D; Penel N; Zhang Y; Ojalvo LS; Hicking C; Rolfe PA; Ihling C; Dussault I; Locke G; Borel C
Front Oncol; 2022; 12():981940. PubMed ID: 36568239
[TBL] [Abstract][Full Text] [Related]
32. Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
Yoo C; Javle MM; Verdaguer Mata H; de Braud F; Trojan J; Raoul JL; Kim JW; Ueno M; Lee CK; Hijioka S; Cubillo A; Furuse J; Azad N; Sato M; Vugmeyster Y; Machl A; Bajars M; Bridgewater J; Oh DY; Borad MJ
Hepatology; 2023 Sep; 78(3):758-770. PubMed ID: 36999533
[TBL] [Abstract][Full Text] [Related]
33. Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer.
Morris VK; Overman MJ; Lam M; Parseghian CM; Johnson B; Dasari A; Raghav K; Kee BK; Huey R; Wolff RA; Shen JP; Li J; Zorrilla I; Tzeng CD; Tran Cao HS; Chun YS; Newhook TE; Vauthey N; Duose D; Luthra R; Haymaker C; Kopetz S
Cancer Res Commun; 2022 Sep; 2(9):979-986. PubMed ID: 36382087
[TBL] [Abstract][Full Text] [Related]
34. NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models.
Xu C; Marelli B; Qi J; Qin G; Yu H; Wang H; Jenkins MH; Lo KM; Lan Y
Transl Oncol; 2022 Feb; 16():101322. PubMed ID: 34954456
[TBL] [Abstract][Full Text] [Related]
35. Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFβ) provides significant antitumor efficacy in immune checkpoint resistant models.
Franks SE; Fabian KP; Santiago-Sánchez G; Wolfson B; Hodge JW
Oncoimmunology; 2022; 11(1):2124666. PubMed ID: 36211806
[TBL] [Abstract][Full Text] [Related]
36. M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine.
Knudson KM; Hicks KC; Luo X; Chen JQ; Schlom J; Gameiro SR
Oncoimmunology; 2018; 7(5):e1426519. PubMed ID: 29721396
[TBL] [Abstract][Full Text] [Related]
37. The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 Pathways.
Birrer MJ; Fujiwara K; Oaknin A; Randall L; Ojalvo LS; Valencia C; Ray-Coquard I
Front Oncol; 2022; 12():814169. PubMed ID: 35280818
[TBL] [Abstract][Full Text] [Related]
38. Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1.
Vugmeyster Y; Grisic AM; Wilkins JJ; Loos AH; Hallwachs R; Osada M; Venkatakrishnan K; Khandelwal A
Cancer Chemother Pharmacol; 2022 Oct; 90(4):369-379. PubMed ID: 36066618
[TBL] [Abstract][Full Text] [Related]
39. Bullous pemphigoid secondary to bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1.
Wiggins CJ; Morris VK; Klimas NK; Nagarajan P; Curry JL; Richards KN
JAAD Case Rep; 2021 Jul; 13():23-25. PubMed ID: 34136620
[No Abstract] [Full Text] [Related]
40. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β.
Lan Y; Zhang D; Xu C; Hance KW; Marelli B; Qi J; Yu H; Qin G; Sircar A; Hernández VM; Jenkins MH; Fontana RE; Deshpande A; Locke G; Sabzevari H; Radvanyi L; Lo KM
Sci Transl Med; 2018 Jan; 10(424):. PubMed ID: 29343622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]